PRINCETON, N.J.–(BUSINESS WIRE) November 16, 2020 — Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has informed the…
Read Morelisocabtagene maraleucel
lisocabtagene maraleucel U.S. Food and Drug Administration (FDA) Accepts for Priority Review Bristol-Myers Squibb’s Biologics License Application (BLA) for Lisocabtagene Maraleucel (liso-cel) for Adult Patients…
Read More